Cigna Stock Slides as Rising Medical Costs Overshadow Earnings Beat

Cigna Corp. (CI) shares fell in Tuesday trading even after the company reported second-quarter earnings and revenue that surpassed analyst expectations and modestly raised its full-year forecast. The negative reaction highlights investor focus on rising medical costs and other underlying concerns that overshadowed the positive headline numbers.

A 'Beat-and-Raise' Met With Skepticism

For the second quarter, Cigna posted adjusted earnings of $7.78 per share on total revenue of $71.7 billion, according to its pre-market report. These figures topped consensus estimates of approximately $7.59 per share and $70.18 billion in revenue.

The health services company also lifted its full-year 2026 adjusted earnings outlook to at least $30.45 per share. This represents a $0.10 increase from its previous projection and sits just slightly above the analyst consensus of approximately $30.41.

Rising Costs Weigh on Sentiment

Despite the stronger-than-expected results, several factors appeared to sour investor sentiment. A key concern was the increase in the Cigna Healthcare segment's medical care ratio (MCR), which rose to 84.5% from 83.2% in the same period last year. A higher MCR indicates that the insurer is spending a larger portion of its premium income on medical claims, squeezing profitability.

Ad

Other factors contributing to the cautious tone included:

• Management's disclosure that a one-time specialty generic benefit boosted Q2 results but would not recur, raising questions about the quality of the earnings beat.
• The report was the first under new CEO Brian Evanko, introducing an element of transition uncertainty.
• Insider sales of approximately $59.4 million over the prior three months created a negative overhang for the stock, the source noted.

Market Context

Cigna's decline was particularly notable as it came on a day of broad market strength, with the S&P 500 and Nasdaq Composite both rallying. This divergence suggests the sell-off was company-specific, reflecting a classic "sell the news" reaction where the magnitude of the earnings beat and guidance raise was deemed insufficient to justify the stock's valuation amid persistent cost pressures.